Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  GROOPMAN JEROME
 2. Date of Event Requiring Statement (Month/Day/Year)
07/24/2013		 3. Issuer Name and Ticker or Trading Symbol
Onconova Therapeutics, Inc. [ONTX]
(Last)
(First)
(Middle)
C/O ONCONOVA THERAPEUTICS, INC., 375 PHEASANT RUN		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

NEWTOWN, PA 18940		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to purchase) 03/09/2006 03/10/2015 Common Stock 375 $ 1.33 D  
Stock Option (right to purchase) 04/26/2006 04/27/2015 Common Stock 375 $ 1.33 D  
Stock Option (right to purchase) 10/06/2006 10/07/2015 Common Stock 750 $ 2.67 D  
Stock Option (right to purchase) 10/19/2006 10/20/2015 Common Stock 1,500 $ 2.67 D  
Stock Option (right to purchase) 01/11/2007 01/12/2016 Common Stock 1,500 $ 2.67 D  
Stock Option (right to purchase) 10/06/2006 10/06/2016 Common Stock 375 $ 2.67 D  
Stock Option (right to purchase) 01/11/2008 01/11/2017 Common Stock 1,500 $ 6 D  
Stock Option (right to purchase) 01/11/2007 01/11/2017 Common Stock 375 $ 6 D  
Stock Option (right to purchase) 02/26/2007 02/26/2017 Common Stock 375 $ 6 D  
Stock Option (right to purchase) 03/06/2007 03/06/2017 Common Stock 375 $ 6 D  
Stock Option (right to purchase) 03/29/2007 03/29/2017 Common Stock 375 $ 6 D  
Stock Option (right to purchase) 05/08/2007 05/08/2017 Common Stock 375 $ 6 D  
Stock Option (right to purchase) 12/31/2008 01/01/2018 Common Stock 2,250 $ 6 D  
Stock Option (right to purchase) 01/16/2008 01/16/2018 Common Stock 375 $ 6 D  
Stock Option (right to purchase) 02/12/2008 02/12/2018 Common Stock 187 $ 6 D  
Stock Option (right to purchase) 05/31/2008 06/01/2018 Common Stock 375 $ 6 D  
Stock Option (right to purchase) 12/31/2012 01/01/2022 Common Stock 2,625 $ 6.13 D  
Stock Option (right to purchase) 06/06/2011 06/06/2021 Common Stock 375 $ 6.13 D  
Stock Option (right to purchase) 01/01/2012 01/01/2021 Common Stock 2,250 $ 6.13 D  
Stock Option (right to purchase) 09/30/2010 09/30/2020 Common Stock 375 $ 6.13 D  
Stock Option (right to purchase) 01/01/2011 01/02/2020 Common Stock 2,250 $ 5.76 D  
Stock Option (right to purchase) 11/30/2009 12/01/2019 Common Stock 375 $ 5.76 D  
Stock Option (right to purchase) 09/29/2009 09/30/2019 Common Stock 375 $ 5.76 D  
Stock Option (right to purchase) 07/23/2009 07/24/2019 Common Stock 375 $ 5.76 D  
Stock Option (right to purchase) 03/24/2009 03/25/2019 Common Stock 375 $ 5.76 D  
Stock Option (right to purchase) 02/20/2009 02/21/2019 Common Stock 187 $ 5.76 D  
Stock Option (right to purchase) 01/01/2010 01/02/2019 Common Stock 2,250 $ 5.76 D  
Stock Option (right to purchase) 09/10/2008 09/11/2018 Common Stock 187 $ 6 D  
Stock Option (right to purchase) 07/22/2008 07/23/2018 Common Stock 187 $ 6 D  
Stock Option (right to purchase) 05/31/2008 06/01/2018 Common Stock 375 $ 6 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
GROOPMAN JEROME
C/O ONCONOVA THERAPEUTICS, INC.
375 PHEASANT RUN
NEWTOWN, PA 18940		   X      

Signatures

/s/ Ajay Bansal, as attorney in fact 07/24/2013
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 
Remarks:
One of Two.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.